Dr Debashis Sarker Academics Senior Lecturer and Consultant in Medical Oncology Contact details debashis.sarker@kcl.ac.uk
Serum immunoglobulin G is associated with decreased risk of pancreatic cancer in the Swedish AMORIS study 14 February 2020 First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma 01 December 2019 Chronic inflammation markers are associated with risk of pancreatic cancer in the Swedish AMORIS cohort study 29 August 2019 Hepatocellular Carcinoma as a Complication of Vascular Disease of the Liver After Fontan Procedure 01 February 2019 Delayed adverse events in phase I trials of molecularly targeted and cytotoxic agents 21 September 2018 First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer 01 September 2018 A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors 07 August 2018 Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial 01 June 2018 Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma 05 April 2018 PAK4 pathway as a potential therapeutic target in pancreatic cancer 01 March 2018